Gemcitabine in the treatment of advanced non-small cell lung cancer: Review of main phase II and III trials;Rôle de la gemcitabine dans la chimiothérapie des stades avancés du cancer bronchique non à petites cellules: Revue des principales études de phase II et III

Anti-Cancer Drugs

Volumn 12, Issue SUPPL. 3, 2001, Pages

  Crino, L ^a   Cappuzzo, F ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

Chemotherapy; Gemcitabine; Non small cell lung cancer; Platinum analogs

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADVANCED CANCER; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

EID: 0034885615     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200107003-00003     Document Type: Conference Paper

References (15)

1. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group Trial
2. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a european multicenter trial including 612 patients
3. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project
4. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
5. Randomized phase III study of gemcitabine-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer
6. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
7. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer
8. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
9. Cisplatin-gemcitabine, vs cisplatin-gemcitabine-vinorelbine, vs cisplatin-gemcitabine-paclitaxel in advanced non-small cell lung cancer. First-stage analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial
10. Gemcitabine, paclitaxel and carboplatin for advanced non-small cell lung cancer
11. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small cell lung cancer
12. Paclitaxel and carboplatin in combination with gemcitabine: A phase I-II trial in patients with advanced non-small cell lung cancer
13. Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer
14. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
15. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor